Articles tagged with Drug Design
Researchers at The Wistar Institute have developed a new, long-lasting antibody treatment called Persistent Multivalent T Cell Engager (CA9-PMTE) that targets clear cell renal cell carcinoma. This innovative therapy has shown promise in pre-clinical models and could potentially be used to treat other difficult-to-treat cancers.
Cleveland Clinic and IBM researchers develop a hybrid framework combining quantum and classical computing methods for protein structure prediction. This approach overcomes limitations of current classical methods and demonstrates improved accuracy in predicting protein structures.
Researchers have designed a method to 'cloak' proteins for targeted delivery into cells, utilizing lipid nanoparticles. The cloaked proteins can be captured by the nanoparticles and exert their therapeutic effect once inside the cell. This approach shows promise for repurposing antibodies and other proteins for cancer treatment.
The study highlights the importance of protease-activated receptors (PARs) in cancer growth and development, with PH-binding motifs identified as a key platform for drug design. The researchers suggest that targeting PARs could provide an alternative to current oncogenic pathways.
Scientists have discovered the transporters responsible for delivering essential nutrients choline and ethanolamine to human cells. The study sheds light on the atomic structure of these transporters and their role in distributing micronutrients throughout the body, providing a foundation for new therapeutic approaches.
Researchers found no significant 'participation effect' in cancer trials, contrary to common belief among patients and healthcare providers. The study's results provide reassurance that not enrolling in a trial doesn't disadvantage a patient's survival outcomes.
A phase 3 trial found that pamrevlumab did not significantly improve lung function in patients with idiopathic pulmonary fibrosis. The study's results underscore the need for effective treatments to slow disease progression and improve patient outcomes.
Nach0 was trained on diverse tasks, including natural language understanding, synthetic route prediction, and molecular generation. The model performed well on molecular tasks using molecular data and outperformed ChatGPT, making it a significant step toward unlocking the full potential of LLMs for drug discovery.
Researchers have developed a synthesis method for introducing difluoromethyl groups into pyridines, a promising approach for new drugs and agrochemicals. The method allows precise introduction of the group at specific sites, overcoming a long-standing challenge in the chemistry field.
Researchers have discovered new binding sites for medications in proteins by heating them to body temperature, revealing previously unknown structures. This breakthrough could lead to the development of more effective drugs for various health conditions, including stroke, heart disease, and diabetes.
Insilico Medicine's lead compound demonstrates strong enzymatic activity, selectivity, and favorable ADME properties, as well as antitumor activity in various animal models. The company's generative AI-powered platform generated over 3,600 candidate molecules before identifying the promising lead compound.
Researchers at Insilico Medicine developed COSMIC, a new framework for molecular conformation space modeling that provides accurate insights into molecule positioning and activity. This enables faster and more efficient drug design decisions.
Researchers at Gladstone Institutes have identified a blood coagulation protein, fibrin, as the culprit behind toxic inflammation and neuron loss after a major head injury. This finding can inform new treatment strategies for traumatic brain injuries, which often lead to dementia, depression, and difficulty concentrating.
Researchers at University of Texas M. D. Anderson Cancer Center have developed a new method for developing immunotherapy drugs using engineered peptides. The approach improved tumor control and prolonged survival in preclinical models of breast cancer.
Researchers from the University of Cambridge used AI to identify compounds that block alpha-synuclein aggregation, a key step in treating Parkinson's disease. This breakthrough could lead to faster development of new treatments for the condition, which affects over six million people worldwide.
Researchers at Insilico Medicine have identified a new class of Polθ inhibitors featuring central scaffolding rings, designed using Chemistry42, with significant enzymatic and cellular potency. The discovery showcases the potential of AI in medicinal chemistry for precise molecular modifications.
Researchers have developed a new treatment that uses tailored doses of anti-cancer drugs released directly into the surgical cavity to treat liver cancer. The approach has shown promise in reducing recurrence rates and minimizing chemotherapy side effects, with potential applications for other types of cancer.
Researchers at Insilico Medicine developed QFASG, a quantum-assisted algorithm generating novel small-molecule structures from fragments. The tool successfully designed inhibitors for cancer-related proteins, showcasing its potential in accelerating drug discovery and development.
A new statistical-modeling workflow can quickly identify molecular structures of products formed by chemical reactions, accelerating drug discovery and synthetic chemistry. The workflow also enables the analysis of unpurified reaction mixtures, reducing time spent on purification and characterization.
Researchers found that nontraditional stroke risk factors like migraines are as important as traditional risk factors like high blood pressure for adults younger than ages 35-45. The association between stroke and nontraditional stroke risk factors was stronger in adults younger than 35 years old.
Researchers have developed a new, synthetic lung surfactant that mimics the functionality of animal-derived formulations. The surfactant has shown promise in reducing surface tension and may offer a cheaper alternative to Infasurf.
Researchers have developed an AI model called SyntheMol that can design new antibiotics against deadly bacteria like Acinetobacter baumannii. The model identified six potent antibacterial compounds with non-toxic properties, offering a potential solution to the global crisis of antibiotic resistance.
Researchers have developed nanoparticles that can inactivate multiple strains of the SARS-CoV-2 virus by targeting its twist in the spike protein. These particles show promise as a complementary treatment for COVID-19 when vaccines and other treatments are ineffective, particularly against vulnerable populations.
A Stanford University research team has developed a potential new anti-coronavirus drug that binds more tightly and durably than current treatments like Paxlovid. The compound, ML2006a4, performed well in preclinical experiments against SARS-CoV-2 variants that have evolved resistance to Paxlovid.
Researchers have demonstrated novel proteins that can efficiently reach intramembrane targets using a customized computer-based approach. The study yields a general computational process for streamlining protein design aimed at intramembrane targets, opening up possibilities for therapeutic applications and understanding signaling mech...
Researchers used generative AI to design a lead molecule for treating fibrosis, a biological process associated with aging. The compound, INS018_055, demonstrated significant efficacy in preclinical studies and showed promising results in clinical trials, accelerating drug discovery and providing new therapeutic options.
A novel antibody constant region variant (REW) extends plasma half-life and improves biodistribution, allowing for both invasive and non-invasive delivery. The REW technology also enhances the complement system, providing enhanced ability to kill cancer cells and bacteria.
PandaOmics uses advanced AI algorithms to process vast quantities of diverse data, performing gene and pathway analysis and target predictions. The platform has been extensively validated in multiple therapeutic areas, including oncology, inflammation, and immunology.
Researchers have developed a new class of antibiotics that can overcome drug-resistant bacteria by targeting the physical and functional integrity of the bacterial cell wall. This could be a game-changer in treating infections, particularly those caused by resistant strains.
University of North Carolina at Chapel Hill researchers have developed a new drug delivery platform that harnesses helical amyloid fibers designed to untwist and release drugs in response to body temperatures. This discovery could be useful in treatment to reverse Alzheimer’s Disease impact by degrading amyloid plaques.
Scientists from IOCB Prague have developed a universal and accurate new computational method to predict how proteins interact with drugs. The SQM2.20 scoring function yields DFT-quality predictions in minutes, significantly accelerating drug discovery.
Researchers develop nanovector nanogels that selectively target glial cells involved in spinal cord injury inflammation, reducing damage and improving recovery. The treatment demonstrates potential for modulating glial cells in neurodegenerative diseases like Alzheimer's.
Scientists have developed a cage-like molecule to trap sulfate in water, which could help control its concentration in health, industry, and environmental management. The molecular trap can be prepared inexpensively from off-the-shelf chemicals and has potential applications in medicine, such as treating cystic fibrosis.
Scientists at the University of California, Riverside, have identified 898 RNA-dependent proteins in the deadliest human malaria parasite, Plasmodium falciparum. These findings could lead to novel therapeutic targets against malaria and highlight the importance of RNAs in biological pathways in the parasite.
Chemical simulations can be sped up by resetting them, a new study from Tel Aviv University found. This technique, called stochastic resetting, overcomes the timescale problem, allowing for more accurate predictions of slow processes.
Researchers have created a genAI model called 'drugAI' that can generate unique molecular structures for potential drugs with high binding affinity and efficacy. The model outperforms traditional methods in terms of speed and cost, opening up new possibilities for disease treatment.
A new study published in the American Heart Association journal Hypertension found that tirzepatide significantly lowered systolic blood pressure levels in nearly 500 adults with obesity. The results suggest treating obesity with this weight loss medication may be an effective strategy for preventing or treating high blood pressure.
Researchers discovered that reducing cholesterol levels in mice with advanced atherosclerosis leads to a decrease in the number of smooth muscle-derived cells causing plaque growth, while preserving stabilizing cell types. This finding opens up new opportunities for targeted therapies.
GIST researchers develop tunable optical properties in nanostructures, enabling applications in wound healing, drug delivery, and secure verification. A clock-inspired design featuring magnesium nano-rotamers demonstrates programmable polarization-resolved coloration.
Researchers discover antibody-dependent enhancement of toxicity (ADET), a phenomenon where antibodies can amplify venom's potency. The breakthrough contributes to expediting the development of a new generation of antivenom, potentially saving millions from snakebites yearly.
Researchers developed a platform combining automated experiments with AI to predict chemical reactivity, greatly accelerating the design process for new drugs. A machine learning model predicts where molecules will react and how reaction sites vary under different conditions, enabling precise tweaks to complex molecules.
Researchers have developed a precise and efficient tool using 'single atom skeletal editing' to insert single carbon atoms into cyclic compounds, enabling ring size adjustment from five to six-membered rings. This approach opens up the way for designing and modifying complex molecular structures with potential industrial applications i...
Researchers at St. Jude Children's Research Hospital have designed a new version of the drug spectinomycin that overcomes efflux, a key mechanism driving antibiotic resistance in Mab infections. The modified compound, eAmSPCs, shows enhanced antimicrobial efficacy and works well with various classes of antibiotics.
Researchers develop nanoparticles that selectively bind to activated astrocytes and microglia cells in the hippocampus of Alzheimer's patients, demonstrating increased nanoparticle transport across the blood brain barrier with age. The study provides valuable insights into advancing nanoparticle-based drug delivery for treating neurode...
Researchers at UChicago find a way to use electricity to boost chemical reactions, improving yields and enabling sustainable synthesis. The study uses electrochemistry to control molecular interactions, offering a unique design lever for greener chemistry.
Researchers have developed a new method to generate cyclic peptides that can target diseases and be administered orally, overcoming challenges in protein binding. The approach enables high-throughput screening and has shown substantial bioavailability in rats, opening possibilities for treating various diseases.
The researchers designed a capsule about the size of a multivitamin, powered by a small battery, which vibrates to activate mechanoreceptors in the stomach. This activation stimulates hormone release patterns similar to those following a meal, reducing food intake and slowing weight gain by 40 percent.
Scientists in Germany developed a new analytical method to precisely elucidate the size of particles, structure, and RNA molecules in pharmaceutical products. This information can help evaluate product quality, enabling improved development of new products.
A team of researchers has discovered a new inactive form of the p38a protein, which is regulated by the cellular redox state. This finding opens up new avenues for developing therapeutic compounds that modulate the activity of p38a more precisely.
Scientists at the University of Washington School of Medicine developed a novel protein design approach using AI, creating proteins that bind to challenging biomarkers with exceptionally high affinity and specificity. The breakthrough has implications for drug development, disease diagnosis, and environmental monitoring.
A new study found that deaths from infective endocarditis decreased overall in the US, but rose sharply among people ages 25-44, likely linked to the opioid crisis. Researchers call for more investigation into the trends and recommend comprehensive care plans including substance use disorder screening and treatment.
Researchers have identified a new enzyme, KtzT, that can form a rare nitrogen-nitrogen bond in molecules. The discovery enables the efficient production of tailored compounds with specific effects on organisms and their metabolic processes.
A new study published in the Journal of the American Heart Association found that many couples around the world share high blood pressure. The research analyzed data from over 50,000 couples in four countries and found a strong association between partners' blood pressure status.
Temperature-sensitive emulsions offer a new method to control when droplets dissolve, enabling precise targeting of medicines to specific areas in the body. The discovery could revolutionize methods of delivering medication in higher concentrations to diseased areas.
Researchers at Gladstone Institutes used CRISPR to destroy glioblastoma cells in an approach that could be applied to other highly mutated cancers. The technique, dubbed "cancer shredding," targets and rapidly eliminates tumor cells while sparing healthy ones.
Researchers at Purdue University have developed a novel cancer immunotherapy compound that targets the enzyme TC-PTP, found in both cancer cells and T cells. Deleting this enzyme promotes antigen presentation, alerting the immune system to tumor cells, while stimulating T-cell activation enhances their ability to fight and destroy tumors.
The ORBITA-2 trial found that stenting improves symptoms compared to a placebo procedure, providing evidence-based treatment for stable chest pain. The study suggests updating guidelines for stable coronary artery disease and offers patients and medical teams two treatment strategies with similar benefits.
A phase 4 clinical trial found that apixaban, an anti-clotting medication, reduced the rate of stroke and blood clots in adults with implanted heart devices experiencing short bouts of asymptomatic, irregular heart rhythms. The study suggests that these individuals may benefit from receiving an anticoagulant.
A new therapeutic, lepodisiran, has shown promising results in reducing lipoprotein(a) levels to undetectable levels for nearly one year. The study found that the medication is safe and effective in lowering Lp(a) levels by more than 94%.
The C-Path Neuroscience Annual Workshop brought together stakeholders to chart a transformative course for neurology research and drug development, focusing on chronic progressive diseases such as Alzheimer's and Parkinson's. Key highlights included recommendations for innovative therapies and tools to address complex disorders.